Cargando…
Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis
BACKGROUND: In accordance with expert guidance, patients have typically continued to receive treatment with subcutaneous interferon beta-1a (sc IFN β-1a) for relapsing multiple sclerosis (MS) during the COVID-19 pandemic. METHODS: We provide a summary of outcomes among sc IFN β-1a-treated patients w...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Authors. Published by Elsevier B.V.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479355/ https://www.ncbi.nlm.nih.gov/pubmed/34619487 http://dx.doi.org/10.1016/j.msard.2021.103283 |